Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2011 May 11

PMID 21556678

Citations 48

Authors

Deborah A Levine

Kenneth M Langa

Affiliations

Soon will be listed here.

Abstract

The prevalence of vascular cognitive impairment (VCI) is likely to increase as the population ages and cardiovascular disease survival improves. We provide an overview of the definition and disease mechanisms of VCI and present a systematic literature review of the current evidence for the pharmacologic and nonpharmacologic therapies used to treat the VCI symptoms of cognitive dysfunction or to modify VCI through primary and secondary prevention. The Cochrane Database of Systematic Reviews was searched from 2005 to October 2010 using the keywords "vascular dementia" or "vascular cognitive impairment and therapy." MEDLINE was searched for English-language articles published within the last 10 years using the combined Medical Subject Headings (MeSH) "therapeutics and dementia," "vascular" or "vascular cognitive impairment." Although cholinesterase inhibitors and memantine produce small cognitive improvements in patients with VCI, these drugs do not improve global clinical outcomes and have adverse effects and costs. Selective serotonin reuptake inhibitors and dihydropyridine calcium channel blockers may improve short-term cognitive function in patients with VCI. Anti-hypertensive therapy with an ACE inhibitor-based regimen and statins may prevent the major subtype of VCI known as poststroke cognitive decline. Clinical and effectiveness studies with long-term follow-up are needed to determine the benefits and risks of pharmacologic and nonpharmacologic therapies to prevent and treat VCI. Given its growing health, social, and economic burden, the prevention and treatment of VCI are critical priorities for clinical care and research.

Citing Articles

Neurobiological Mechanisms Underlying Psychological Dysfunction After Brain Injuries.

Unadkat P, Rebeiz T, Ajmal E, De Souza V, Xia A, Jinu J Cells. 2025; 14(2).

PMID: 39851502 PMC: 11763422. DOI: 10.3390/cells14020074.

Prevalence of disability and associated functional limitations among older adults in Brazil.

Souto R, Corassa R, Souto Junior J, Morais Neto O PLOS Glob Public Health. 2024; 4(11):e0003225.

PMID: 39541406 PMC: 11563409. DOI: 10.1371/journal.pgph.0003225.

Self-perceived cognitive fluctuations and their relationship to everyday functioning in older adults with and without HIV disease.

Lorkiewicz S, Webber T, Sober J, Kiselica A, Woods S Clin Neuropsychol. 2024; 38(5):1085-1108.

PMID: 38914007 PMC: 11196870. DOI: 10.1080/13854046.2023.2282728.

Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases.

Rahman M, Islam R, Bhuiyan M Front Pharmacol. 2024; 15:1374408.

PMID: 38659577 PMC: 11041382. DOI: 10.3389/fphar.2024.1374408.

Citicoline: pharmacological and clinical review, 2022 update.

Secades J, Gareri P Rev Neurol. 2022; 75(s05):S1-S89.

PMID: 36544369 PMC: 10548480. DOI: 10.33588/rn.75s05.2022311.

References

Wong C, Bansback N, Lee P, Anis A . Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. Can J Neurol Sci. 2009; 36(6):735-9. DOI: 10.1017/s0317167100008350. View

Richard E, Van den Heuvel E, Moll van Charante E, Achthoven L, Vermeulen M, Bindels P . Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord. 2009; 23(3):198-204. DOI: 10.1097/WAD.0b013e31819783a4. View

Sachdev P . Is it time to retire the term "dementia"?. J Neuropsychiatry Clin Neurosci. 2000; 12(2):276-9. DOI: 10.1176/jnp.12.2.276. View

Kavirajan H, Schneider L . Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007; 6(9):782-92. DOI: 10.1016/S1474-4422(07)70195-3. View

Dichgans M, Markus H, Salloway S, Verkkoniemi A, Moline M, Wang Q . Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008; 7(4):310-8. DOI: 10.1016/S1474-4422(08)70046-2. View

Auchus A, Brashear H, Salloway S, Korczyn A, De Deyn P, Gassmann-Mayer C . Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007; 69(5):448-58. DOI: 10.1212/01.wnl.0000266625.31615.f6. View

Ukraintseva S, Sloan F, Arbeev K, Yashin A . Increasing rates of dementia at time of declining mortality from stroke. Stroke. 2006; 37(5):1155-9. DOI: 10.1161/01.STR.0000217971.88034.e9. View

McGuinness B, Todd S, Passmore P, Bullock R . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009; (4):CD004034. PMC: 7163274. DOI: 10.1002/14651858.CD004034.pub3. View

Napryeyenko O, Borzenko I . Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007; 57(1):4-11. DOI: 10.1055/s-0031-1296579. View

10.

Cohen R, Browndyke J, Moser D, Paul R, Gordon N, Sweet L . Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. Cerebrovasc Dis. 2003; 16(3):199-204. DOI: 10.1159/000071116. View

11.

Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer R . Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009; 28(1):75-80. PMC: 2814023. DOI: 10.1159/000231980. View

12.

Wilcock G, Mobius H, Stoffler A . A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002; 17(6):297-305. DOI: 10.1097/00004850-200211000-00005. View

13.

Iadecola C, Gorelick P . Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003; 34(2):335-7. DOI: 10.1161/01.str.0000054050.51530.76. View

14.

Quaney B, Boyd L, McDowd J, Zahner L, He J, Mayo M . Aerobic exercise improves cognition and motor function poststroke. Neurorehabil Neural Repair. 2009; 23(9):879-85. PMC: 3024242. DOI: 10.1177/1545968309338193. View

15.

Jorge R, Acion L, Moser D, Adams Jr H, Robinson R . Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010; 67(2):187-96. PMC: 3718472. DOI: 10.1001/archgenpsychiatry.2009.185. View

16.

Jin Y, Di Legge S, Ostbye T, Feightner J, Hachinski V . The reciprocal risks of stroke and cognitive impairment in an elderly population. Alzheimers Dement. 2009; 2(3):171-8. DOI: 10.1016/j.jalz.2006.03.006. View

17.

Snowdon D, Greiner L, Mortimer J, Riley K, Greiner P, Markesbery W . Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997; 277(10):813-7. View

18.

Zuliani G, Guerra G, Ranzini M, Rossi L, Munari M, Zurlo A . High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia. Int J Geriatr Psychiatry. 2006; 22(4):305-11. DOI: 10.1002/gps.1674. View

19.

Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T . Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2010; 10(1):43-53. DOI: 10.1016/S1474-4422(10)70250-7. View

20.

Qiu C, Winblad B, Fratiglioni L . The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005; 4(8):487-99. DOI: 10.1016/S1474-4422(05)70141-1. View